Related Experiment Videos

Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial

M Marchand1, E Fuseau, D J Critchley

  • 1EMF Consulting, Aix en Provence, France.

Journal of Pharmacokinetics and Pharmacodynamics
|January 20, 2010
PubMed

Insights

Rufinamide effectively treats Lennox-Gastaut syndrome (LGS) seizures. Co-administration with valproate in patients under 30 kg necessitates a lower maximum daily rufinamide dose (600 mg) for safety and efficacy.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Neurology

Background:

  • Rufinamide is approved for Lennox-Gastaut syndrome (LGS) seizures in patients aged 4+.
  • Population pharmacokinetic (PK) data from epilepsy studies, including LGS, established rufinamide's PK profile.
  • Demographic factors and drug-drug interactions (DDIs) with antiepileptic drugs (AEDs) were investigated using population PK modeling.

Purpose of the Study:

  • To explore rufinamide exposure under various dosing regimens in LGS patients through clinical trial simulations.
  • To identify optimal rufinamide doses for safe and efficacious use in broader patient populations.
  • To establish evidence-based dosing recommendations for rufinamide, particularly concerning valproate co-administration.

Main Methods:

  • Population PK modeling was employed to analyze pooled data from clinical epilepsy studies.
  • Two distinct DDI models were developed and compared to assess interactions with other AEDs.
  • Clinical trial simulations were conducted to evaluate rufinamide exposure across different dosing scenarios.

Main Results:

  • Coadministration of valproate was found to decrease rufinamide clearance, indicating a need for dose adjustment.
  • Simulations revealed greater inter-individual variability in rufinamide concentrations for patients <30 kg, partly due to higher valproate levels.
  • A lower maximum daily dose of 600 mg rufinamide was proposed for patients <30 kg receiving concomitant valproate, versus 1000 mg without valproate.

Conclusions:

  • The study provides crucial insights into rufinamide pharmacokinetics and the impact of valproate co-administration.
  • Dosing recommendations are established to optimize rufinamide therapy in LGS patients, especially those with lower body weight.
  • These findings support safe and effective adjunctive treatment of LGS seizures with rufinamide, considering potential DDIs.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...